May 13, 2020 / 01:00PM GMT
Yang Huang - BofA Merrill Lynch, Research Division - Research Analyst
Thank you, everyone, for joining the presentation today. I'm Yang Huang, Bank of America China health care analyst, covering Zai Lab. And today, we are glad that we invited Tao Fu, President and the CEO of Zai Lab, to give us a presentation to introduce recent business and the pipeline updates. Hi, Tao.
Tao Fu - Zai Lab Limited - President, COO & Director
Hi, Yang. Thank you very much. First and foremost, I hope everyone is safe and healthy during the coronavirus pandemic. I would like to thank Yang and the Bank of America team for having Zai Lab at the conference. So if you can go to the slide presentation. Slide 2 is our disclaimer.
Moving on to Slide 3. The last 6 months has been a truly transformational period for Zai Lab as we achieved regulatory approval in Mainland China for our lead product, ZEJULA, for second-line ovarian cancer. ZEJULA approval transformed Zai Lab to a commercial-stage company in Mainland China and we're in full launch mode in 2020. ZEJULA is the first
Zai Lab Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers